Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:10:37.808Z.
Calculation as of: 2026-10-06T17:10:37.808Z.
Quote observation: 2026-10-06T17:10:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dce8aa4241063aa413a511fcc73ca02083e5b5875564fe7763a0d28183f25b54
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $236.66M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $236.60M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $237.69M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $236.33M | N/A | 10.01 | 8.82 | 11.38 |
| InflaRx N.V. (IFRX)vs › | $237.88M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $239.72M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $232.96M | N/A | 28.08 | 28.08 | 28.08 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $240.70M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $241.04M | N/A | 2.96 | 2.96 | 2.96 |
| Q32 Bio Inc. (QTTB)vs › | $242.28M | 2.92 | 4.27 | 4.27 | 3.78 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.88
Forward EPS (Est.)
$-0.14
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
